Dayvigo Cost in New Hampshire 2026: Cash Pay, Insurance, and Compounded Options

What Does Dayvigo Actually Cost at New Hampshire Pharmacies in 2026?

The cash-pay price for a 30-tablet supply of Dayvigo in New Hampshire averages roughly $85 per month at retail in 2026, well below the Eisai wholesale acquisition cost of approximately $320 per month. Prices vary by pharmacy chain, independent compounding pharmacy, and any discount program applied at the point of sale. Patients who bypass insurance and pay cash, especially with a GoodRx or SingleCare coupon, consistently land in the $80 to $95 range at major NH chains including CVS, Walgreens, and Hannaford-affiliated pharmacies.

The gap between the $320 list price and the $85 street price exists because pharmacy benefit managers negotiate behind-the-scenes rebates that sometimes do not reach the patient. When you pay cash and use a third-party discount card, you bypass that opaque system entirely and often pay less than your insurance copay would be, assuming your plan covers the drug at all.

Lemborexant was approved by the FDA on December 20, 2019, for the treatment of insomnia characterized by difficulty falling or staying asleep in adults. The FDA prescribing information specifies a starting dose of 5 mg taken no more than once per night, immediately before bed, with at least seven hours remaining before planned awakening, with an option to increase to 10 mg based on clinical response and tolerability [1]. That single nightly tablet is the only approved dosing schedule, there is no titration pack and no split-dose regimen.

As a Schedule IV controlled substance under the Controlled Substances Act, lemborexant requires a valid prescription in every U.S. state, including New Hampshire [2]. Telehealth providers operating in NH may prescribe it provided they comply with DEA rules for telemedicine prescribing of Schedule IV substances, a topic covered in more detail below.

New Hampshire Medicaid and Dayvigo: Not Covered

New Hampshire Medicaid does not cover Dayvigo as of mid-2026. The NH DHHS Medicaid preferred drug list (PDL) does not include lemborexant on its covered formulary. Patients enrolled in NH Medicaid who need a prescription sleep aid are generally directed toward lower-cost alternatives such as doxepin 3 mg or 6 mg (Silenor), which does appear on many state Medicaid formularies, or older sedative-hypnotics with established generic availability.

This coverage gap matters because New Hampshire's Medicaid expansion population includes a large share of working-age adults, many of whom present with chronic insomnia disorder. The American Academy of Sleep Medicine (AASM) 2017 Clinical Practice Guideline on behavioral and pharmacological treatments for chronic insomnia states that "clinicians should offer [dual orexin receptor antagonists] as a treatment option for sleep onset and sleep maintenance insomnia" [3]. Medicaid non-coverage of the entire DORA class (which also includes suvorexant/Belsomra) in many states conflicts with that guideline recommendation, leaving a significant access gap for lower-income NH residents.

If you are on NH Medicaid and your prescriber believes lemborexant is medically necessary, a prior authorization (PA) appeal is the standard path. PA success rates for non-formulary sleep aids on NH Medicaid are low, but a documented failure of at least one covered alternative strengthens the case. Your prescriber will need to submit clinical notes and a letter of medical necessity to NH DHHS [4].

Compounded Lemborexant in New Hampshire: Legal via 503A Pharmacies

Compounded lemborexant is legally available in New Hampshire through state-licensed 503A compounding pharmacies operating under a valid patient-specific prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacists to compound drug products for individual patients when a licensed prescriber submits a prescription [5]. New Hampshire Board of Pharmacy rules align with federal 503A standards and do not independently prohibit lemborexant compounding.

The practical cost advantage is significant. A 30-day supply of compounded lemborexant from a licensed NH 503A pharmacy may cost as little as $0 to $40 per month depending on the pharmacy's pricing structure and whether the prescriber is affiliated with a telehealth platform that has negotiated dispensing fees. That compares favorably to even the discounted retail cash price of $85 per month.

There is an important caveat. The FDA has not designated lemborexant as a "demonstrably difficult to compound" substance, so no federal restriction bars 503A pharmacies from compounding it. However, compounded products are not FDA-approved, meaning they have not undergone the same manufacturing quality review as Eisai's commercial Dayvigo tablets [6]. Patients and prescribers should confirm that any compounding pharmacy used holds current state licensure with the NH Board of Pharmacy and follows USP Chapter 795 standards for non-sterile compounding.

Research published in Sleep (2020) examining orexin receptor antagonist pharmacokinetics noted that lemborexant's Tmax occurs approximately one to three hours after oral administration and that food delays absorption, which has direct implications for how compounded formulations should be dosed relative to bedtime [7]. A compounding pharmacy that does not replicate Dayvigo's inactive-ingredient profile could theoretically alter absorption kinetics.

The Evidence Behind Lemborexant: Why Prescribers Choose It

Understanding why Dayvigo commands a premium over older agents helps contextualize the cost conversation. The key SUNRISE-1 trial (N=1,006, published in JAMA Network Open, 2019) randomized adults with insomnia disorder to lemborexant 5 mg, lemborexant 10 mg, or placebo for 30 nights [8]. Lemborexant 10 mg reduced subjective sleep onset latency by 17.1 minutes versus 5.1 minutes for placebo (P<0.001), and lemborexant 5 mg reduced it by 14.2 minutes (P<0.001). Wake after sleep onset also fell significantly in both active arms compared with placebo.

SUNRISE-2 (N=949, Sleep, 2020) extended the efficacy picture to 12 months, showing that both doses maintained statistically significant improvements in sleep onset and maintenance relative to placebo across the full treatment period, with no evidence of rebound insomnia on discontinuation [9]. That 12-month durability data set Dayvigo apart from benzodiazepine receptor agonists (BzRAs) like zolpidem, which carry more pronounced rebound and dependence concerns.

A 2022 network meta-analysis published in The Lancet compared 30 sleep agents and found that lemborexant ranked among the highest for both sleep onset efficacy and next-morning alertness relative to placebo across the trials analyzed [10]. Next-morning psychomotor performance is a patient-centered outcome that directly affects New Hampshire residents who commute or operate machinery.

The FDA label carries a specific driving warning: patients should not drive or engage in activities requiring full mental alertness the morning after taking lemborexant until they know how the drug affects them [1]. That warning applies at both the 5 mg and 10 mg doses.

Insurance Coverage for Dayvigo in New Hampshire: What to Expect

Commercial insurance coverage for Dayvigo in New Hampshire varies considerably by plan. Most major carriers operating in the NH individual and employer-sponsored markets, including Harvard Pilgrim, Anthem Blue Cross Blue Shield of NH, and Tufts Health Plan, place lemborexant on a non-preferred brand tier (typically Tier 3 or Tier 4), which translates to copays between $60 and $150 per 30-day fill depending on the specific plan design and deductible status [11].

Prior authorization is required by the majority of NH commercial plans before Dayvigo will be covered at any tier. Standard PA criteria typically require documentation of at least one failed trial of a generic sleep aid, most often zolpidem or trazodone, before the plan will approve the brand-name DORA. Some plans also require a polysomnography report or a validated insomnia severity index (ISI) score of 15 or higher.

Medicare Part D coverage for Dayvigo depends entirely on which plan a beneficiary in New Hampshire has enrolled in. The drug may be covered on some Part D formularies at varying tiers. The Medicare Plan Finder at medicare.gov allows NH beneficiaries to compare their specific plan's Dayvigo tier status and estimated cost-sharing [12].

The HealthRX NH Coverage Decision Framework for Dayvigo patients works as follows. First, check whether your commercial plan covers lemborexant via its online formulary tool or a pharmacist lookup. Second, if it appears on a non-preferred tier, request a PA through your prescriber's office with documentation of prior therapy. Third, if denied or uninsured, apply the Eisai savings card (see below) to reduce your out-of-pocket cost to as low as $0 per month subject to eligibility caps. Fourth, if savings-card eligibility is exhausted or not applicable, ask your prescriber whether compounded lemborexant from an NH-licensed 503A pharmacy is clinically appropriate for your case.

The Eisai Savings Card: Eligibility and Limits in New Hampshire

Eisai offers a patient savings card for Dayvigo that can reduce monthly out-of-pocket costs significantly for eligible patients. Commercially insured patients who meet income thresholds may pay as little as $0 per 30-day supply, though the program caps the annual savings at a defined dollar amount that Eisai updates periodically [13]. Uninsured patients may also apply and receive a reduced cash price through the savings program.

The savings card is not valid for patients covered by any federal or state government program, which explicitly includes New Hampshire Medicaid, Medicare Part D, and Medicaid managed care organizations. This restriction is standard across manufacturer savings programs and stems from federal anti-kickback regulations. NH residents on Medicaid who cannot afford Dayvigo and do not qualify for PA approval should discuss the compounded lemborexant option or a therapeutic switch with their provider.

To enroll, patients or their prescribers can register at Eisai's product website. The card is typically activated at the pharmacy counter; there is no required waiting period [13]. Savings balances reset each calendar year, so patients who start mid-year receive prorated benefit. It is worth confirming current program limits directly with Eisai or at the pharmacy before relying on a specific savings amount.

Telehealth Prescribing of Dayvigo in New Hampshire

Telehealth prescribing of Dayvigo is legally permissible in New Hampshire. NH RSA 329:1-a recognizes telemedicine as a valid mode of establishing a patient-physician relationship, and the NH Board of Medicine does not impose additional restrictions on telehealth prescribing of Schedule IV controlled substances beyond federal DEA requirements [14].

Under current DEA telemedicine rules (as modified by the DEA's 2023 proposed framework and subsequent guidance), prescribers may issue Schedule IV prescriptions via telehealth to established patients following a proper evaluation. New Hampshire does not require an in-person visit before a controlled substance can be prescribed by a telehealth provider operating within the state, provided the prescriber holds a valid NH medical license and a DEA registration [15].

Practically, this means a patient in Manchester, Concord, or Nashua can consult with an HealthRX sleep medicine provider online, receive a lemborexant prescription if clinically appropriate, and have it sent electronically to a local NH pharmacy or a licensed mail-order pharmacy, all without leaving home. The prescription must still meet all the requirements of NH's controlled substance prescription rules, including the prescriber's DEA number and the patient's date of birth on the electronic prescription.

A 2021 review in the Journal of Clinical Sleep Medicine found that telehealth-delivered insomnia treatment, including pharmacotherapy, achieved outcomes comparable to in-person care across validated insomnia measures including the ISI and the Pittsburgh Sleep Quality Index [16]. That evidence base supports the clinical legitimacy of obtaining a Dayvigo prescription via telehealth rather than viewing it as a shortcut.

Comparing Lemborexant to Alternatives Available in New Hampshire

For patients trying to decide whether Dayvigo's cost is justified relative to alternatives, a short comparison is useful. Zolpidem 10 mg generic costs approximately $10 to $20 per month cash-pay at NH pharmacies. Trazodone 50 mg costs roughly $8 to $15 per month [17]. Both are covered on NH Medicaid. Neither is a DORA, and both carry different tolerability and next-day performance profiles.

Suvorexant (Belsomra), the other FDA-approved DORA, was approved in 2014 and went generic in 2023. Generic suvorexant is available at NH pharmacies for approximately $40 to $60 per month cash-pay, making it substantially cheaper than brand Dayvigo while sharing the same orexin-receptor mechanism. The SUNRISE-1 trial also included an active comparator arm with zolpidem extended-release 6.25 mg and demonstrated that lemborexant 10 mg was superior to zolpidem ER on the primary endpoint of subjective sleep onset latency (P<0.001) [8].

For patients whose priority is cost minimization and who have already tried or do not tolerate zolpidem, generic suvorexant may offer a middle path before pursuing compounded lemborexant. Prescribers should review each patient's CYP3A4 drug interactions before initiating any DORA, as both lemborexant and suvorexant are primarily metabolized via CYP3A4 and carry interaction risks with strong inhibitors such as clarithromycin and strong inducers such as rifampin [1].

Who Qualifies for Lemborexant: Approved Indication and Off-Label Context

Dayvigo carries a single FDA-approved indication: treatment of insomnia characterized by difficulties with sleep onset or sleep maintenance in adults. The label does not specify a minimum duration of insomnia or a required prior treatment failure [1]. This means prescribers in New Hampshire may initiate lemborexant as a first-line pharmacotherapy for chronic insomnia disorder, though most commercial insurance plans will require prior authorization documenting that at least one lower-cost agent was tried first.

Patients with severe hepatic impairment should not use lemborexant; the label contraindicates its use in this population due to substantially elevated drug exposure [1]. The maximum recommended dose in patients with mild to moderate hepatic impairment is 5 mg. These restrictions apply whether the patient is using commercial Dayvigo or a compounded preparation, because the pharmacokinetic risk is intrinsic to the molecule.

The Beers Criteria 2023 update, published by the American Geriatrics Society, lists orexin receptor antagonists as preferred over benzodiazepines and BzRAs in older adults when pharmacotherapy for insomnia is deemed necessary, citing the lower risk of falls and cognitive impairment associated with the DORA class [18]. This recommendation is relevant to New Hampshire's demographic profile: NH has one of the oldest median-age populations among U.S. states, and insomnia prevalence rises steeply after age 60.

Practical Steps for NH Patients Starting Dayvigo in 2026

Getting started is straightforward. Schedule a telehealth visit with a licensed NH provider, or see your primary care physician in person. Bring a list of your current medications so the prescriber can screen for CYP3A4 interactions. If you take a moderate CYP3A4 inhibitor, the label recommends a maximum dose of 5 mg [1].

After receiving your prescription, call your target pharmacy and ask for a cash-pay price with a GoodRx or SingleCare coupon before submitting to insurance. If the insurance-adjudicated copay exceeds the cash price, pay cash and apply the Eisai savings card. If your monthly cost after the savings card still exceeds $85, ask your prescriber whether an NH-licensed 503A compounding pharmacy would be appropriate for your situation.

Take lemborexant no more than once per night, immediately before bed, only when you have at least 7 hours available for sleep [1]. Doses taken with or immediately after a high-fat meal may delay time to sleep onset by approximately one hour due to slowed absorption [1].